amifostine anhydrous has been researched along with Cancer of Liver in 12 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 9.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 5.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "The primary objective was to assess the efficacy of any medical intervention to prevent hearing loss in children with cancer treated with platinum-based therapy (that is including cisplatin, carboplatin and/or oxaliplatin) when compared to placebo, no additional treatment or a different protective medical intervention." | 4.90 | Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. ( van As, JW; van Dalen, EC; van den Berg, H, 2014) |
| "A total of 92 patients with colorectal cancer or gastric cancer were enrolled, and randomly assigned to receive amifostine (500 mg/m2)(amifostine group, 46 patients) or glutamine (1500 mg/m2) (control group, 46 patients) just before oxaliplatin infusion." | 2.73 | [Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors]. ( Fan, QX; Lu, P; Wang, LX; Wang, RL; Wang, X; Zong, H, 2008) |
| "At the moment there is no evidence from individual studies in children with osteosarcoma and hepatoblastoma treated with different platinum analogues and dosage schedules which underscores the use of amifostine as an otoprotective intervention as compared to no additional treatment." | 2.48 | Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. ( van As, JW; van Dalen, EC; van den Berg, H, 2012) |
| " In this study, the pharmacokinetic parameters of 5-FU are monitored in six patients, who received two chemotherapeutic courses of 2,600 mg/m2 BSA 5FU over 24 h, one course with 700 mg/m2 BSA amifostine prior to the 5-FU infusion and the other without." | 1.31 | Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma. ( Fuhlroth, J; Martens-Lobenhoffer, J; Ridwelski, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van As, JW | 2 |
| van den Berg, H | 2 |
| van Dalen, EC | 2 |
| Lu, P | 1 |
| Fan, QX | 1 |
| Wang, LX | 1 |
| Wang, X | 1 |
| Zong, H | 1 |
| Wang, RL | 1 |
| Sullivan, MJ | 1 |
| Anderson, JR | 1 |
| Krailo, M | 1 |
| Feng, M | 1 |
| Smith, DE | 2 |
| Normolle, DP | 1 |
| Knol, JA | 1 |
| Pan, CC | 1 |
| Ben-Josef, E | 1 |
| Lu, Z | 2 |
| Feng, MR | 1 |
| Chen, J | 2 |
| Ensminger, W | 1 |
| Lawrence, TS | 2 |
| Kusenda, Z | 1 |
| Kerger, J | 1 |
| Awada, A | 1 |
| Geurs, F | 1 |
| Van Vreckem, A | 1 |
| Habboubi, N | 1 |
| Piccart, MJ | 1 |
| Martens-Lobenhoffer, J | 1 |
| Fuhlroth, J | 1 |
| Ridwelski, K | 1 |
| Mönig, H | 1 |
| Sedlmeier, H | 1 |
| Oehlert, W | 1 |
| Konermann, G | 1 |
| Messerschmidt, O | 1 |
| Byfield, JE | 1 |
| Glover, D | 1 |
| Glick, JH | 1 |
| Weiler, C | 1 |
| Fox, K | 1 |
| Guerry, D | 1 |
2 reviews available for amifostine anhydrous and Cancer of Liver
| Article | Year |
|---|---|
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
Topics: Adolescent; Amifostine; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Child; Child, Preschool; | 2014 |
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
Topics: Adolescent; Amifostine; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Child; Child, Preschool; | 2012 |
3 trials available for amifostine anhydrous and Cancer of Liver
| Article | Year |
|---|---|
[Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors].
Topics: Amifostine; Antineoplastic Agents; Colonic Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasm | 2008 |
A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy.
Topics: Adult; Aged; Amifostine; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; C | 2012 |
Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
Topics: Adult; Aged; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplas | 1997 |
7 other studies available for amifostine anhydrous and Cancer of Liver
| Article | Year |
|---|---|
Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.
Topics: Amifostine; Cisplatin; Clinical Trials as Topic; Hearing Loss; Hepatoblastoma; Humans; Infant; Inter | 2009 |
The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
Topics: Amifostine; Child; Clinical Trials Data Monitoring Committees; Clinical Trials, Phase III as Topic; | 2011 |
Determination of WR-1065 in human blood by high-performance liquid chromatography following fluorescent derivatization by a maleimide reagent ThioGlo3.
Topics: Amifostine; Chromatography, High Pressure Liquid; Drug Stability; Humans; Liver Neoplasms; Mercaptoe | 2005 |
Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
Topics: Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C | 2000 |
Prolonged radioprotective activity of WR-2721 linked to dextran.
Topics: Amifostine; Animals; Dextrans; Liver; Liver Neoplasms; Male; Mice; Neoplasms, Radiation-Induced; Org | 1990 |
Combined use of drugs and radiation in the treatment of liver metastases.
Topics: Amifostine; Bromodeoxyuridine; Combined Modality Therapy; Floxuridine; Fluorouracil; Humans; Infusio | 1986 |
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; | 1987 |